Having absorbed other study stumbles in the past few months, the company now has halted development of dalzanemdor in treating Huntington’s disease after top-line phase II data showed it missed a ...
The U.S. FDA added hidradenitis suppurativa to the label for UCB SA’s Bimzelx (bimekizumab-bkzx), throwing renewed light on the indication, a chronic disease that causes painful, boil-like lumps that ...
In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...
United Commercial Bank PLC (UCB) has recently opened two new branches in Mainamati and Basurhat, respectively, with a view to providing top-notch banking services to the residents of these areas.
But how will Trump’s second White House reign fare for the biopharma industry? It’s a question that remains to be seen. The president-elect’s “concepts of a plan” regarding healthcare ...
Kennedy, Jr. might play in healthcare. With the U.S. electing Donald Trump to a second presidential term, biopharma analysts were cautiously optimistic Wednesday about the prospects for the ...
The week after seeing its partner Roche cut and run, UCB has reported the failure of its anti-tau antibody bepranemab to improve cognition and function in people with early Alzheimer’s disease.
UCB reported Thursday that a Phase 2 study for its anti-tau Alzheimer’s program bepranemab did not meet its primary endpoint.
BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Venture investments into biopharma and medtech continued their 2024 upswing during the third quarter, according to a new report from J.P. Morgan commercial banking. Biopharma startups raised $6.6 ...